Theravance Biopharma, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Theravance Biopharma (TBPH) Tops Q3 EPS by 5c, Revenues Miss
November 6, 2018 4:57 PM ESTTheravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($1.10), $0.05 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $14.06 million.
Rick E Winningham, chairman and chief executive officer, commented: "The steps we have taken over the course of the year reflect a focus on our strategic... More
